Nutrition in Gastrointestinal Diseases

Published on 20/05/2015 by admin

Filed under Gastroenterology and Hepatology

Last modified 20/05/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 5 (1 votes)

This article have been viewed 518 times

CHAPTER 5 Nutrition in Gastrointestinal Diseases

It has long been known that nutritional status affects clinical outcome. In lean healthy people, death has been associated with weight loss of more than 35%, protein storage loss of more than 30% and fat storage loss of more than 70%. Clinicians spend a considerable amount of time treating patients but give little attention to the signs and symptoms of nutritional inadequacies or imbalances. As practicing clinical gastroenterologists, we have a responsibility to understand the science of nutrition and to become familiar with the nutrition literature. The literature detailing nutrition as medical therapy is controversial. Overall, there is a lack of large, randomized, prospective studies comparing one nutritional therapy with another; thus, meta-analyses often are used to group small studies and allow reasonable conclusions.

NUTRITIONAL ASSESSMENT

Determining who is at risk for malnutrition is a complicated science. A proper nutritional assessment provides a mechanism whereby patients who may require nutritional support can be identified and also provides a gauge to monitor the effectiveness of such support (see Chapter 4).

IMMUNOLOGIC TESTS

The serum total lymphocyte count has been correlated with changes in nutritional status, especially protein depletion.5 However, no prospective study has shown this to be a reliable marker of a patient’s nutritional status.

CALORIC ASSESSMENT

Mathematical Equations

Calculation of energy requirements can be obtained through mathematical equations. Many different methods of estimating energy needs have been used over the years, including estimations based on body surface area, body weight, body height, and age of the patient. The most commonly used equation for calculating energy needs is the Harris-Benedict equation.10 The calculation is as follows:

Men:

image

Women:

image

where W = weight in kilograms, A = age, and L = height in centimeters.

This calculation of energy needs is multiplied by stress factors to arrive at a patient’s overall caloric needs (Table 5-1) Other caloric assessment formulas commonly used include the Ireton-Jones equation and the Mifflin-St. Jeor formula.11 Calculated energy needs, however, may over- or underestimate a patient’s true energy needs, especially in patients with complicated disease processes that can alter their metabolic rate.12 In these cases, direct measurements of overall energy needs may be more appropriate.

Table 5-1 Influence of Disease Severity (Physiologic Stress) on Resting Energy Expenditure (REE)

DISEASE SEVERITY REE (%)
Mild 10
Moderate 25
Severe 50

Example: REE of 1500 kcal in a patient with moderate disease = (1500 kcal × 0.25) + 1500 kcal = 1875 kcal/day.

Indirect Calorimetry

Direct measurements of a patient’s energy needs can be performed using indirect calorimetry, which measures heat produced by oxidation. A ventilated hood is placed over the resting patient’s head and its oxygen and carbon dioxide content for two hours is analyzed. From this information, the resting energy expenditure (REE) is derived. True caloric needs are calculated by multiplying the REE by an activity or stress factor. In addition, a patient’s respiratory quotient (RQ) is derived. The RQ is equal to Vco2 (volume of CO2)/Vo2 (volume of O2). An RQ of approximately 0.7 or less is an indication of underfeeding whereas an RQ of approximately 1.0 or more is an indication of overfeeding.13 Indirect calorimetry plays a large role in obese or very malnourished patients, for whom determining caloric needs based on total body weight can be inaccurate.14 More recently, simple hand-held devices have been developed with an oxygen sensor for energy measurement. By breathing through the device for 10 minutes, the patient’s REE can be determined (Fig. 5-3).15 This tool has been shown to be as effective as the more expensive and laborious indirect calorimetry device in patients who can spontaneously breathe on their own volition, that is, those who are not on a ventilator.16

NUTRIENT SUBSTRATES

MACRONUTRIENTS

The macronutrients that fuel human metabolism include carbohydrates, fats, and proteins. The major source of energy in the human diet is carbohydrate, which constitutes almost half of the typical American diet. Carbohydrate is consumed as starch, sucrose, or lactose. Starch is made up of the polysaccharides amylopectin and amylose. Sucrose and lactose are disaccharides. Most digestion occurs in the duodenum and small intestine (see Chapter 100).17 Starch digestion begins in the mouth with the enzyme amylase and continues with the pancreatic enzyme alpha-amylase in the small intestine. Starch is broken down into oligosaccharides. The oligosaccharides and disaccharides are hydrolyzed by the small intestinal brush border to monosaccharides by glucoamylase, sucrase, and amylase. Glucose and galactose are absorbed across the small intestinal mucosa by active transport, whereas fructose moves across by facilitated diffusion.18

Dietary fat is primarily composed of triglycerides, which consist mainly of four long-chain fatty acids—palmitic, stearic, oleic, and linoleic—with smaller amounts of linolenic acid and medium-chain triglycerides (MCTs). Linoleic and linolenic acids are essential fatty acids; that is, they cannot be synthesized from nondietary sources. Essential fatty acid deficiency can result in a clinical syndrome consisting primarily of a scaly erythematous rash.19 Clinically, this may be seen in patients completely dependent on PN for their nutrient intake who receive no fat in their daily PN solution over a period of one to two weeks. Triglycerides are hydrolyzed to free fatty acids and beta-monoglycerides by pancreatic lipase and colipase.20 Because fats are insoluble in water, their digestion requires a unique environment involving an emulsification process whereby bile salts enhance their absorption (see Chapter 100). In water, bile salts form a micelle with a hydrophobic core and a hydrophilic periphery. Micellar contents diffuse across the water layer, intestinal mucosa, and cell membrane and enter the cell. Here they are reesterified to triglycerides and linked to an apoprotein to form a chylomicron.

MCTs have a different mechanism of absorption; 30% are absorbed directly as intact triglycerides and the remaining 70% are digested to medium-chain fatty acids, which are soluble in water and directly absorbed by the small intestinal mucosa. MCT-based diets may be helpful for patients with fat malabsorption from pancreatic or liver disease. A diet very high in MCT and low in long-chain triglycerides (LCTs), however, can lead to essential fatty acid deficiency. These patients present with a characteristic diffuse, scaly, erythematous skin rash. Fats provide a long-term energy source for patients who are experiencing starvation. Unfortunately, critically ill catabolic patients lose their ability to use fat for energy efficiently, making them more dependent on their carbohydrate and protein stores.

Protein and amino acid metabolism are essential to provide the building blocks necessary to create a variety of body proteins and nitrogen-containing compounds. Proteins are composed of amino acids joined by peptide bonds. There are 22 amino acids, eight of which are essential: lysine, threonine, leucine, isoleucine, valine, methionine, phenylalanine, and tryptophan; two others, histidine and arginine, are essential for infants and growing children. Dietary proteins are partially digested by pepsin in the stomach to form polypeptides, but most protein digestion is performed in the duodenum and upper jejunum by pancreatic proteases, including trypsin, chymotrypsin, carboxypeptidase, and elastase (see Chapter 100).21 Peptides are further hydrolyzed in the small intestine by aminopeptidases, enzymes found in the brush border of the small intestine, to free amino acids and very small peptides. Large peptides must be hydrolyzed by brush border enzymes for absorption to occur, whereas dipeptides and tripeptides can move intact into mucosal cells.22

MACROMINERALS

Minerals account for only 4% of total body weight, yet they serve as essential cofactors, help maintain fluid osmotic pressures, and provide the proper environment for many chemical reactions (see Chapter 4).

Calcium

This is the most abundant cation in the human body. Bone and teeth contain about 99% of total body calcium. It is ingested in the form of an insoluble salt and must be released from its salt form to its ionized form for absorption (see Chapter 100).23 Calcium absorption occurs along the length of the small intestine and is vitamin D–dependent. In periods of restricted calcium intake, the colon may become more involved in calcium homeostasis by increasing its absorption. In periods of low serum calcium levels, renal excretion of calcium is reduced and bone calcium stores are released. Magnesium and calcium compete with one another for absorption. Unabsorbed dietary fat can interfere with calcium absorption by the formation of soaps in the intestine, which are excreted in the feces. The recommended daily intake of calcium is 800 mg/day for adults and 1200 mg/day for growing children. Calcium requirements are higher for pregnant women and older adults. In addition to bone mineralization, calcium also is important in blood clotting, muscle contraction, and the secretory activity of most endocrine and exocrine cells. Hypocalcemia may result in tetany, paresthesias, hyperreflexia, seizures, and mental status changes. Chronic calcium deficiency will result in rickets in children and osteomalacia in adults.

Magnesium

This is the second most abundant intracellular cation. Approximately 60% of magnesium is located in bone.24 Skeletal muscle also serves as another large source of magnesium storage. Magnesium absorption increases when magnesium intake is low. Vitamin D may affect absorption, although this relationship is not clear. Patients on a low-protein diet also can have difficulty with magnesium absorption. The recommended daily intake of magnesium is 300 to 500 mg/day. Magnesium is important in providing stability to the structure of ATP and is involved in numerous other enzyme systems. Magnesium deficiency can result in tetany, ataxia, myoclonus, coma, psychosis, cardiac dysrhythmias, and hypotension. Severe hypomagnesemia may be seen in patients with refeeding syndrome.

MICRONUTRIENTS

Essential micronutrients are present in minute or trace amounts in the body, sometimes in quantities less than 100 µg (see Chapter 4). Although trace elements are present in very small amounts, they often have dramatic effects; deficiencies are more common than toxicity. Deficiencies can result from reduced intake, decreased bioavailability, decreased transport proteins, excess excretion, or as the result of certain disease states. Many of these deficiencies develop in patients who are on long-term PN or who are severely malnourished. Assessment of trace element deficiency is extremely difficult (Table 5-2) because serum levels may not accurately reflect body stores. Therefore, clinicians may have to depend largely on physical signs and symptoms to detect micronutrient deficiency.

Table 5-2 Daily Trace Element Requirements

TRACE ELEMENT Requirement
ENTERAL PARENTERAL
Chromium 30 µg 10-15 µg
Copper 0.9 mg 0.3-0.5 mg
Fluoride 4 mg Not well defined
Iodine 150 µg Not well defined
Iron 18 mg Not routinely added
Manganese 2.3 mg 60-100 µg
Molybdenum 45 µg Not routinely added
Selenium 55 µg 20-60 µg
Zinc 11 mg 2.5-5 mg

From American Society for Parenteral and Enteral Nutrition. Guidelines for the use of parenteral and enteral nutrition in adults and pediatric patients. J Parenter Enteral Nutr 2002; 26:29SA-33SA.

Copper

This is important for normal body iron uptake. A microcytic hypochromic anemia can be seen with copper deficiency,26 a result of shortened red blood cell lifespan. Copper plays a major role in taste sensation and is important in reducing the potential injurious effects of free radicals. Copper is excreted in bile and should be replaced in those with external biliary drains or excessive diarrhea. The daily requirement is approximately 1.5 to 3 µg/day.

VITAMINS

Vitamins (see Chapters 4, 100) are essential micronutrients involved in basic body functions such as growth, tissue maintenance, and metabolism. They are broadly classified as water-soluble or fat-soluble. Absorption of fat-soluble vitamins requires absorption and transport of lipids. Water-soluble vitamins, except vitamin C, are part of a B-complex group (Table 5-3).

Table 5-3 Daily Reference Intakes* and Sites of Absorption of Vitamins

VITAMIN RECOMMENDED DIETARY ALLOWANCE* ABSORPTION SITES
C 75-90 mg Distal small intestine
B1 (thiamine) 1.1-1.2 mg Jejunum
Riboflavin 1.1-1.3 mg Proximal small intestine
Niacin 14-16 mg Stomach, small intestine
Pantothenic acid 5 mg Jejunum
Biotin 30 µg Unknown
Folic acid 400 µg Jejunum
B12 2-4 µg Distal ileum
B6 1.3-1.7 µg Jejunum
A 700-900 retinol equivalents Proximal small intestine
D 200-600 IU Duodenum, terminal ileum
E 15 mg/day Mid–small intestine
K 90-120 µg/day Jejunum, ileum, colon

* Daily Reference Intakes (DRI) were established by the Institute of Medicine between 1997-2001. They are quantitative estimates of nutrient intakes to be used for planning and assessing diets for healthy people. The DRIs include both recommended intakes and tolerable upper intake levels. The RDAs (Recommended Dietary Allowances) are a component of the DRIs and are defined as the daily intake of a nutrient considered sufficient to meet the requirements of 97% to 98% of adults.

A retinol equivalent is 3.3 IU of vitamin A; 1 retinol equivalent = 6 µg β-carotene or 1 µg retinol.

Water-Soluble Vitamins

Folic Acid

This is present in many foods including leafy vegetables, fruit, and liver. Polyglutamate forms of folate must be hydrolyzed by jejunal mucosal enzymes prior to absorption.29 Folate serves as a carbon donor in a number of synthetic reactions. The maturation of red blood cells and other short-lived cells is folate-dependent. Folate deficiency results in a macrocytic anemia because of decreased deoxyribonucleic acid (DNA) synthesis. Excessive folate ingestion may produce malaise, insomnia, and gastrointestinal distress.

Fat-Soluble Vitamins

NUTRITION IN SPECIFIC DISEASE STATES

Nutritional assessment and directed nutritional therapy are important in the treatment of many gastrointestinal diseases, and familiarity with appropriate nutritional intervention is imperative to obtaining good clinical outcomes.

INTESTINAL FAILURE (SHORT BOWEL SYNDROME)

Intestinal failure or short bowel syndrome results from loss or disease of the intestine, or both, to an extent that precludes adequate digestion and absorption (see Chapter 103); Crohn’s disease (see Chapter 111), intestinal trauma, and intestinal infarction (see Chapter 114) are the most common causes. The patient often presents with weight loss, diarrhea, dehydration, and weakness. Following extensive resection of the small intestine, intestinal rehabilitation (goal of resuming oral nutrition) of the remaining small intestine is more likely to be successful if the colon has been preserved and the ileocecal valve is maintained.31 The nutritional management of short bowel syndrome depends on the amount and location of small bowel removed. Initially, proton pump inhibitors are used to reduce gastric hypersecretion and anticholinergic agents are used to slow intestinal transit. Parenteral nutrition is prescribed to meet nutritional needs. Oral feedings are gradually started and the volume of PN is reduced as oral feedings are tolerated. If the patient has had a partial ileal resection and has an intact colon, cholestyramine can be used to reduce bile salt–induced diarrhea. In patients with a small amount of ileum remaining and an intact colon, however, the use of cholestyramine can increase diarrhea by creating a relative bile salt deficiency. Vitamin B12 should be given monthly. In patients with significant small bowel resections (80 to 100 cm remaining), a trial of a small-peptide, low-fat, enteral formula should be attempted to reduce the amount of PN the patient requires. Later, a polymeric enteral formula can be substituted. Patients with less than 80 cm of small intestine remaining and no colon often are PN-dependent. The use of somatostatin to reduce intestinal secretions and slow transit time remains controversial.32 Anticholinergic therapy should be initiated. Patients may require larger doses of anticholinergics than usually are recommended, because absorption of the oral medication is limited.

The use of growth hormone, glutamine, and a rice-based diet in an attempt to cause small bowel mucosal hypertrophy and better absorption is controversial. Early data have suggested very significant improvements in small intestinal absorptive function,33 not confirmed by subsequent studies.34 The use of a glycoprotein (GL-2) also has been postulated as a small intestine mucosal stimulator for improved absorption. A recent prospective evaluation of its efficacy noted a statistically significant reduction in PN use35; the effectiveness of this therapy is still being evaluated in additional studies.

PANCREATITIS

Nutritional support is imperative for patients with severe acute pancreatitis or relapsing chronic pancreatitis (see Chapters 58 and 59). Early PN appears to be associated with a reduction in the complications and mortality associated with acute pancreatitis compared with maintaining the patient on an NPO regimen.36 However, central line catheter sepsis rates are high and hyperglycemia is common. Enteral nutrition also has been used in patients with pancreatitis in contrast to previous beliefs that complete bowel rest was required. It appears that intrajejunal feedings are safe and well tolerated.37 A standard, fat-containing, polymeric enteral formula can be used.38 Randomized, prospective trials have shown a reduction in overall patient complications, hospital length of stay, and total hospital charges compared with the use of PN.39,40 The use of jejunal feeding in patients with chronic pancreatitis has been described to improve weight and reduce abdominal pain associated with eating.41 Gastric feedings also have been used successfully in patients with severe acute pancreatitis,42 but are still a topic of investigation.

CROHN’S DISEASE

Crohn’s disease (see Chapter 111) is sometimes associated with malnutrition.43 These patients often are hypermetabolic and may have anorexia because of nausea and abdominal pain. Deficiencies of magnesium, selenium, potassium, and zinc are common in inflammatory bowel disease (IBD) as a result of losses in diarrheal fluids and through fistula tracts.44 Dietary therapy in IBD always has been considered important, but no specific diet can be recommended. Fat restriction may be important in patients with ileal disease or those who have undergone an ileal resection. The use of EN can be an important component of IBD therapy for patients who cannot eat. Enteral nutrition has not proven superior to PN in inducing remissions in IBD,45 although it is less costly and associated with fewer complications. Enteral nutrition alone has not proven superior to drug therapy for the treatment of Crohn’s disease.46 The use of PN in IBD should be restricted to patients who have not responded to conservative medical therapy (EN and medications) or in whom EN cannot be delivered.

LIVER DISEASE

Nutritional deficiencies are common among patients with liver disease, mainly from decreased dietary intake, but also as a result of altered metabolism, decreased nutrient storage, and increased nutrient requirements (see Chapters 72, 92, and 93). Decreased nutrient intake is secondary to anorexia and nausea and is more common in patients with cirrhosis.47 Decreased bile salt production results in an intolerance to high-fat foods and the development of fat-soluble vitamin malabsorption. In addition, hypoalbuminemia results in edema of the mucosa of the small intestine, further compromising nutrient absorption. Depletion of muscle mass occurs secondary to a lack of adequate glucose stores and a dependency on protein stores for energy. Normal serum amino acid concentrations are altered, with a rise in aromatic amino acids (tyrosine, phenylalanine, and methionine) and a fall in branched-chain amino acids (valine, leucine, and isoleucine). The aromatic amino acids normally are removed by the liver; it is postulated that the rise in aromatic amino acids precipitates hepatic encephalopathy because they act as false neurotransmitters. Moreover, branched-chain amino acids are used preferentially as a protein source by patients in liver failure because they require minimal liver catabolism. Unfortunately, studies have failed to demonstrate improved outcomes in liver-failure patients fed a branched-chain amino acid–fortified diet or enteral solution.48 There is a general tendency to limit protein intake in patients with cirrhosis to prevent encephalopathy; however, these patients have an increased protein demand and further limiting their protein intake will only accelerate protein calorie malnutrition. It is preferable to feed patients according to their protein needs and treat encephalopathy with medications as it develops. Parenteral nutrition should be used with caution in patients with liver failure, because immune dysfunction places these patients at increased risk for catheter sepsis. In addition, the lack of liver glycogen stores can lead to episodes of hypoglycemia when patients are rapidly tapered off PN. Nutritional support prior to liver transplantation has been shown to improve patient outcome, especially in patients who are significantly malnourished prior to the transplantation.49

DIVERTICULAR DISEASE

Patients with diverticular disease (see Chapter 117) often are provided with incorrect nutritional information. They are told to avoid nuts or foods that contain seeds because of fear that the hard small particles may lodge in diverticula and precipitate diverticulitis. There are no clinical data to support this concept,50 and most data suggest that a high-fiber diet will reduce the occurrence of symptomatic diverticular disease.51 Patients hospitalized for complicated diverticular disease can remain symptom-free on a high-fiber diet.52 Fiber intake should be at least 25 g/day and should be provided as insoluble fiber, such as that contained in wheat bran, bran muffins, and fiber-based cereals. The use of probiotics has had some success in the treatment of and prevention of diverticulitis, although more work needs to be done in this area.53

DUMPING SYNDROME

Dumping syndrome is common after partial gastrectomy and vagotomy. Hypertonic gastric contents empty rapidly into the small intestine, and consequently up to 25% of plasma volume suddenly may be transferred to the small intestine.54 Nausea, cramping, diaphoresis, and palpitations develop. Nutritional therapy for dumping syndrome aims to deliver a lower osmolarity solution to the small intestine by the frequent ingestion of small meals containing fat, protein, and complex carbohydrates, but limited in simple sugars. Fluid intake should be restricted and separated from solid food intake to avoid rapid gastric transit. High pectin-containing foods (bananas, oranges) will slow gastric output.

CELIAC DISEASE

Small intestinal mucosal injury and consequent malabsorption in celiac disease (see Chapter 104) occur when a susceptible patient ingests gluten-containing foods such as wheat, barley, rye, or possibly oats. Patients, especially younger ones, present with classic signs of malabsorption, including diarrhea, cramping, and marked weight loss and often develop folate, iron, and fat-soluble vitamin deficiencies. The primary treatment is a gluten-free diet. Wheat starch free of gliadin forms the basis for most bread in a gluten-free diet. Corn, rice, and buckwheat are allowed. Most patients will improve with dietary management. The vast majority of commercially available EN products, if required, are gluten-free.

CANCER

Protein-calorie malnutrition is a common problem in cancer patients. Cancer cachexia is the consequence of multiple metabolic abnormalities induced by the tumor. Appetite stimulation has been used successfully in cancer patients with mild malnutrition.55 The routine use of aggressive nutritional support in all patients receiving chemotherapy and radiation is controversial. Prospective randomized studies have failed to show improved tolerance to chemotherapy with the use of nutritional support,56 and PN also has failed to show an improvement in morbidity from radiation therapy. Parenteral nutrition has been shown to be beneficial for patients with gastrointestinal obstruction from primary or metastatic tumors.57 Parenteral nutrition also has been found to be beneficial in patients following bone marrow transplantation who have developed severe gastrointestinal mucositis.58 Enteral nutrition has been used successfully in patients with head and neck cancer to prevent weight loss, reduce hospitalizations, and reduce interruptions in chemotherapy and radiotherapy. In summary, the use of nutritional support in the cancer patient should be restricted to those patients with a reasonable life expectancy who are likely to be unable to maintain their nutritional needs for a prolonged period. It is in these patients that an improved quality of life may occur.

OBESITY

Obesity is a disease that has had explosive growth, simultaneously affecting many individuals in a community without regard to age, gender, or ethnic origin (see Chapter 6).59 Traditionally, the gastroenterologist has been involved in the endoscopic management of postbariatric surgical complications, including stomal stenosis, gastrointestinal bleeding, and fistulization (see Chapter 7). Previous endoscopic technologies used to treat obesity endoscopically, such as the gastric balloon, had limited exposure in the United States and were removed from the market because of associated complications, such as balloon deflation with migration and resultant small intestinal obstruction. Internationally, however, balloon endoscopic therapy continues, with a number of favorable outcomes reported.60,61 Patients with obesity-related gastrointestinal disease, such as gastroesophageal reflux disease, always have been a staple of the gastroenterologist’s practice. Today, gastroenterologists find themselves on the front line with other physicians attempting to combat obesity and its associated complications, including assessment of patients for risk, identification of those who may benefit from weight loss therapy, and determination of the appropriate weight loss intervention, including management of therapy-associated complications.

Assessing patients with obesity generally takes into consideration the BMI, waist circumference, and comorbid disease states. A person with a BMI more than 30 kg/m2 is considered obese. Patients who are overweight (BMI, 25 to 30 kg/m2) with comorbid diseases should be offered dietary management, exercise, and behavioral therapy. Patients with a BMI more than 30 kg/m2 also should be offered medical management (Table 5-4). If these patients have comorbid diseases, they also should be offered pharmacotherapy (weight loss medications). Patients with a BMI more than 35 kg/m2 should be offered medical management and pharmacotherapy. Surgical therapy is recommended for patients with a BMI more than 35 kg/m2 with significant comorbid diseases and who have not responded to medical management and pharmacotherapy. Patients with a BMI more than 40 kg/m2 should be offered medical management, pharmacotherapy, and surgery.

An enlarged waist circumference also places a patient at higher medical disease risk, separate from comorbid diseases, and correlates well with total body fat.62 Men with a waist circumference more than 40 inches or women with a waist circumference more than 35 inches have a higher risk, similar to the presence of significant comorbid diseases in a man with a BMI more than 30 kg/m2. These patients would be offered pharmacotherapy in addition to medical management, similar to the management of a patient with a BMI more than 30 kg/m2 with significant comorbid disease.

Surgical management of obesity in the United States typically involves a Roux-en-Y gastric bypass, vertical banded gastroplasty, or gastric banding (see Fig. 7-1). In general, most weight is lost in the first year.63 Gastric bypass surgery has a reasonable five-year outcome for maintenance of successful weight loss, but there is an associated mortality (0.5% to 2%) and complications associated with surgical therapy, some of them very significant.64,65

NUTRITIONAL THERAPY

PARENTERAL NUTRITION

For patients with a nonfunctioning gastrointestinal tract, nutrients can be delivered directly into the venous system via a process referred to as parenteral nutrition (PN); nutrients can be delivered into a central vein (central parenteral nutrition, CPN) or a peripheral vein (peripheral parenteral nutrition, PPN).

PN delivers a solution consisting of water, electrolytes, amino acids, carbohydrates, fats, proteins, vitamins, and trace elements. These compounds are mixed and delivered over a period of time, usually 12 to 24 hours. Table 5-5 details a typical CPN formula. A CPN solution is six times more concentrated than blood (1800 to 2400 mOsm/L) and generally consists of approximately 30 to 50 g of protein and 1000 to 1200 cal/L. Determination of caloric and protein needs is based on a prior nutritional assessment.66 Table 5-6 provides an approximation of a patient’s daily protein and calorie needs based on the severity of the disease processes. These needs could be used instead of more complicated formulas presented earlier in this chapter for determining calorie and protein requirements. Overall, daily water requirements are estimated at 20 to 30 mL/kg.

Table 5-5 Sample Central Parenteral Nutrition Order*

COMPONENT AMOUNT
Amino acids 220 kcal/L (55 g protein)
Dextrose 555 kcal/L (163 g carbohydrates)
Lipids 400 kcal/L (40 g of lipids), total: 1175 kcal/L
Sodium 70 mEq/L
Potassium 35 mEq/L
Calcium 5 mEq/L
Magnesium 5 mEq/L
Phosphorus 15 mmol/L
Chloride, acetate To balance
Multivitamins (MVI-13) Industry standard
Trace elements (MTE-5) Industry standard
Drug additives/L (heparin, insulin, H2 blockers) Individualized

* Volume: 2000 mL (83 mL/hr over 24-hr infusion).

Table 5-6 Calorie and Protein Needs Based on Degree of Physiologic Stress

Buy Membership for Gastroenterology and Hepatology Category to continue reading. Learn more here
PHYSIOLOGIC STRESS CALORIE NEEDS (KCAL/KG/DAY) PROTEIN NEEDS (G/KG/DAY)
Mild 25-28 0.8-1.0